16 recruiting. 16 Phase 2, 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Recruiting 16 |
| Phase 1 | 9 | Recruiting 9 |
Follow Liposarcoma: new trials by email Literature Review of Liposarcoma trials Research Report on Liposarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma Lifileucel - Sarcoma, Soft Tissue Sarcoma (STS) | Phase 2 | Recruiting | Iovance Biotherapeutics, Inc. | 80 | 2026-10-02 | 2026-10-09 |
| Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma Abemaciclib, Biopsy Procedure, Biospecimen Collection - Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2026-03-18 | 2026-10-21 |
| Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2026-01-26 | 2026-01-28 |
| Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma preoperative, Quality of life, Functional outcome - Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 110 | 2026-01-26 | 2026-01-28 |
| A Study of Pembrolizumab in People With Ultra-Rare Sarcomas Pembrolizumab - Sarcoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 32 | 2025-12-04 | 2026-07-28 |
| Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors SA53-OS (phase 1), SA53-OS (phase 2) - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Lamassu Bio Inc | 55 | 2025-06-16 | 2026-11-09 |
| STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas STC-15 in combination with toripalimab, STC-15 monotherapy - Solid Tumor, Sarcoma | Phase 1 / Phase 2 | Recruiting | STORM Therapeutics LTD | 107 | 2025-05-05 | 2026-10-22 |
| IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) Tislelizumab+liposomal doxorubicin+ifosfamide - Soft Tissue Sarcomas, Angiosarcoma | Phase 2 | Recruiting | Fudan University | 45 | 2025-02-25 | 2026-01-08 |
| A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma Mirdametinib, Palbociclib - Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 54 | 2025-02-19 | 2026-09-16 |
| Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors Silmitasertib, Irinotecan, Temozolomide - Neuroblastoma, Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | Milton S. Hershey Medical Center | 104 | 2024-10-30 | 2026-10-06 |
| A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) Pemigatinib, Retifanlimab - Dedifferentiated Liposarcoma | Phase 2 | Recruiting | Lund University Hospital | 33 | 2024-06-20 | 2026-08-27 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors APG-115, Toripalimab - Liposarcoma, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Ascentage Pharma Group Inc. | 95 | 2021-05-26 | 2025-02-26 |
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors PF-07220060, Letrozole, Fulvestrant - Liposarcoma, Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Pfizer | 430 | 2020-09-23 | 2026-10-28 |
| Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Trabectedin, Radiotherapy - Liposarcoma, Myxoid, Sarcoma, Soft Tissue | Phase 1 / Phase 2 | Recruiting | Grupo Espanol de Investigacion en Sarcomas | 199 | 2014-11-01 | 2023-05-31 |
Sarcoma (10) · Leiomyosarcoma (8) · Histiocytoma, Malignant Fibrous (4) · Sarcoma, Synovial (4) · Dermatofibrosarcoma (3) · Fibrosarcoma (3) · Hemangiosarcoma (3) · Liposarcoma, Myxoid (3) · Neurofibrosarcoma (3) · Desmoplastic Small Round Cell Tumor (2) · Osteosarcoma (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Chondrosarcoma, Extraskeletal Myxoid (1)
Neoplasms (16) · Neoplasms by Histologic Type (16) · Neoplasms, Connective and Soft Tissue (16) · Neoplasms, Adipose Tissue (15) · Neoplasms, Muscle Tissue (9) · Neoplasms, Connective Tissue (7) · Neoplasms, Fibrous Tissue (6) · Sarcoma (6) · Histiocytoma (4) · Neoplasms, Nerve Tissue (4) · Neoplasms, Vascular Tissue (3) · Nervous System Diseases (3) · Nervous System Neoplasms (3) · Neurofibroma (3) · Neuromuscular Diseases (3)
Doxorubicin (2) · Ifosfamide (2) · toripalimab (2) · Biopsy (1) · Clinical Trials, Phase I as Topic (1) · Clinical Trials, Phase II as Topic (1) · Docetaxel (1) · Fulvestrant (1) · Gemcitabine (1) · Injections (1) · Irinotecan (1) · Letrozole (1) · Midazolam (1) · Proton Therapy (1) · Quality of Life (1)
Memorial Sloan Kettering Cancer Center (2) · Oslo University Hospital (2) · Ascentage Pharma Group Inc. (1) · Fudan University (1) · Grupo Espanol de Investigacion en Sarcomas (1) · HRYZ Biotech Co. (1) · Iovance Biotherapeutics, Inc. (1) · Lamassu Bio Inc (1) · Lund University Hospital (1) · Milton S. Hershey Medical Center (1) · National Cancer Institute (NCI) (1) · Pfizer (1) · STORM Therapeutics LTD (1) · St. Jude Children's Research Hospital (1)
United States (9) · China (4) · Norway (3) · Argentina (1) · Canada (1) · Czechia (1) · France (1) · Italy (1) · Japan (1) · Mexico (1) · Slovakia (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Ivar Hompland, MD, PhD (2) · Kjetil Boye, MD, PhD (2) · Chandrika Behura, MD (1) · Elise F Nassif (1) · Gabi Hanna, MD (1) · Jessica Gartrell, MD (1) · Olayode Babatunde, MD (1) · Robert Maki, MD, MPH (1) · Sandra Tong, MD (1) · Xing Zhang (1) · Ye Guo, MD, PhD (1) · Zhang Xing (1)
PMID 31143880, PMID 32077895, PMID 32827353
UM1CA186688 (1)